Soligenix, Inc., released information regarding its performance and accomplishments in the second quarter on Thursday.
“We continue to be very encouraged with the positive results demonstrated in our Phase 2 oral mucositis trial with SGX942 and expect to report long-term safety data during the fourth quarter of this year,” Christopher Schaber, president and CEO at Soligenix, said. “We have engaged the regulatory authorities in both the US and Europe, and anticipate having a pivotal Phase 2b/3 study design of SGX942 during the first half of next year. We also continue to actively enroll patients in our pivotal Phase 3 study in cutaneous T-cell lymphoma with SGX301. We continue to advance the development of RiVax and OrbeShield in our biodefense business segment, and are pleased with the government agencies additional non-dilutive funding of more than $8 million through newly awarded funding and the exercise of options in support of these programs. The continued support of these programs demonstrates the productive collaboration between the company and the government agencies.”
The company’s accomplishments include receiving additional funding from the Biomedical Advanced Research and Development Authority and the National Institute of Allergy and Infectious Diseases to advance preclinical development of OrbeShield as a medical countermeasure in the treatment of gastrointestinal acute radiation syndrome, as well as positive preliminary proof-of-concept results in the development of a heat-stable subunit Ebola vaccine, the presentation of preliminary results from its SGX942 Phase 2 clinical trial in oral mucositis at the Multinational Association for Supportive Care in Cancer, and the exercised option for the evaluation of RiVax to fund animal efficacy and toxicology studies.
Soligenix is a late-stage biopharmaceutical company specializing in products to treat rare diseases where there is an unmet medical need.